Send to

Choose Destination
J Nucl Med. 2018 Mar 9. pii: jnumed.117.204032. doi: 10.2967/jnumed.117.204032. [Epub ahead of print]

Update on 18F-fluciclovine PET for prostate cancer imaging.

Author information

Emory University School of Medicine, United States.


Positron emission tomography (PET) is a functional imaging method that can exploit various aspects of tumor biology to enable greater detection of prostate cancer than can be provided by morphologic imaging alone. Anti-1-amino-3-[18F]-flurocyclobutane-1-carboxylic acid (18F-fluciclovine) is a non-naturally occurring amino acid PET radiotracer that is recently United States Food and Drug Administration approved for detection of suspected recurrent prostate cancer. The tumor imaging features of this radiotracer mirror the upregulation of transmembrane amino acid transport that occurs in prostate cancer due to increased amino acid metabolism for energy and protein synthesis. This continuing medical education article provides an overview on 18F-fluciclovine PET diagnostic capabilities for primary and metastatic disease, including reviews of published comparisons to conventional imaging and other molecular imaging agents. Additionally, imaging procedure and interpretation is detailed including physiologic and pathologic uptake patterns and pitfalls.


FACBC; Molecular Imaging; Oncology: GU; PET; amino acid; fluciclovine; prostate cancer


Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center